# Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms

Source: https://onco.cc/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/  
OnCo record `paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In 232 Swedish early triple-negative cancers, half were PD-L1-positive by the atezolizumab test (SP142 IC 1%) but only 27% by the pembrolizumab threshold (22C3 CPS 10), and the two tests picked partly different patients.

## Summary

PD-L1 by SP142 immune-cell score and 22C3 combined positive score was compared in 232 early-stage TNBC patients from the population-based SCAN-B cohort. Positivity was 50.9% for SP142 IC 1% or more, 27.2% for 22C3 CPS 10 or more, 53.9% for CPS 1 or more and 41.8% for 22C3 IC 1% or more. Concordance between SP142 IC-positive and the three 22C3 scores was 73.7% (kappa 0.48), 81.5% (0.63) and 86.6% (0.73). CD274 mRNA correlated with every scoring (Spearman 0.59 to 0.62). PD-L1 positivity and TILs were favourable prognostic factors in chemotherapy-treated patients, strongest for CPS 10 and distant relapse-free interval (HR 0.18), but PD-L1 was not independent of TILs.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Journal: Breast Cancer Research
- Year: 2023
- DOI: 10.1186/s13058-023-01724-2
- Authors: Sigurjonsdottir G, De Marchi T, Ehinger A, et al.
- Findings: SP142 IC 1% or more 50.9%; 22C3 CPS 10 or more 27.2%; CPS 1 or more 53.9%.; SP142 versus CPS 10 agreement weak (kappa 0.48).; PD-L1 was prognostic but not independent of tumour-infiltrating lymphocytes.
- What it means: This is the population-based prevalence for the two label thresholds in early TNBC, and it shows the KEYNOTE-355 CPS 10 gate would admit only about a quarter of unselected patients.
- Caveats: Early-stage surgical specimens; the trials scored metastatic biopsies.; Single Swedish region.

## Sources

- Sigurjonsdottir et al., Breast Cancer Res 2023: SP142 versus 22C3 in 232 population-based early TNBCs (SCAN-B): https://doi.org/10.1186/s13058-023-01724-2
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37817263/

## Connected records

- biomarkers: [PD-L1 CPS (combined positive score)](https://onco.cc/biomarkers/pd-l1-cps/), [PD-L1 IC score (immune-cell score, SP142)](https://onco.cc/biomarkers/pd-l1-ic-score/)
- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [PD-L1 IHC 22C3 pharmDx](https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [VENTANA PD-L1 (SP142) Assay](https://onco.cc/drugs/ventana-pd-l1-sp142/)
- institutions: [Skåne University Hospital / Lund University Cancer Centre](https://onco.cc/institutions/lund-skane/)
- terms: [Combined positive score (CPS)](https://onco.cc/terms/cps/), [Immunohistochemistry (IHC)](https://onco.cc/terms/ihc/), [Tumour-infiltrating lymphocytes (TILs)](https://onco.cc/terms/tils/)
- journals: [Breast cancer research](https://onco.cc/journals/breast-cancer-research/)
- trials: [KEYNOTE-355](https://onco.cc/trials/keynote-355/)

---
JSON: https://onco.cc/api/v1/entities/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023.json